Monthly Archives: March 2018

http://www.lslog.com/as-hemophilia-market-heats-up-roche-confirms-5-hemlibra-patient-deaths/As hemophilia market heats up, Roche confirms 5 Hemlibra patient deaths

As hemophilia market heats up, Roche confirms 5 Hemlibra patient deaths

As hemophilia market heats up, Roche confirms 5 Hemlibra patient deaths Roche confirmed that five patients taking its newly launched hemophilia drug Hemlibra have died. The news follows reports last […]

http://www.lslog.com/urovant-starts-pursuit-of-astellas-overactive-bladder-drug-myrbetriq-with-new-phase-3-trial/Urovant starts pursuit of Astellas’ overactive bladder drug Myrbetriq with new phase 3 trial

Urovant starts pursuit of Astellas’ overactive bladder drug Myrbetriq with new phase 3 trial

Urovant starts pursuit of Astellas’ overactive bladder drug Myrbetriq with new phase 3 trial A little later than expected, Roivant group company Urovant has started its confirmatory phase 3 program […]

http://www.lslog.com/bristol-myers-opdivo-yervoy-combo-scores-again-at-fda-this-time-in-colorectal-cancer/Bristol-Myers' Opdivo-Yervoy combo scores again at FDA, this time in colorectal cancer

Bristol-Myers' Opdivo-Yervoy combo scores again at FDA, this time in colorectal cancer

Bristol-Myers’ Opdivo-Yervoy combo scores again at FDA, this time in colorectal cancer Last August, Bristol-Myers Squibb’s Opdivo nabbed an approval to treat specific types of colorectal cancer. And Tuesday, it […]

http://www.lslog.com/doctors-expect-enthusiasm-for-allergans-high-flying-zeltiq-to-fade-survey/Doctors expect enthusiasm for Allergan's high-flying Zeltiq to fade: survey

Doctors expect enthusiasm for Allergan's high-flying Zeltiq to fade: survey

Doctors expect enthusiasm for Allergan’s high-flying Zeltiq to fade: survey Allergan’s fat-fighting Zeltiq has been on a tear as of late, but doctors aren’t expecting that trend to last as […]

http://www.lslog.com/chinas-adagene-raises-50m-to-take-anticancer-antibodies-into-the-clinic/China’s Adagene raises $50M to take anticancer antibodies into the clinic

China’s Adagene raises $50M to take anticancer antibodies into the clinic

China’s Adagene raises M to take anticancer antibodies into the clinic Sequoia China has powered Adagene to a $50 million series C round. The investment positions the Chinese antibody discovery […]

http://www.lslog.com/singapores-aslan-stalks-86m-ipo-to-fund-cancer-pipeline/Singapore’s Aslan stalks $86M IPO to fund cancer pipeline

Singapore’s Aslan stalks $86M IPO to fund cancer pipeline

Singapore’s Aslan stalks M IPO to fund cancer pipeline With a pivotal data readout for lead drug varlitinib due next year, Aslan Pharma has pushed the button on a U.S. […]

http://www.lslog.com/as-sanofi-buyout-nears-ablynx-lupus-drug-flunks-midphase-trial/As Sanofi buyout nears, Ablynx lupus drug flunks midphase trial

As Sanofi buyout nears, Ablynx lupus drug flunks midphase trial

As Sanofi buyout nears, Ablynx lupus drug flunks midphase trial A phase 2 trial of Ablynx’s vobarilizumab in systemic lupus erythematosus (SLE) has missed its primary endpoint. The setback tarnishes […]

http://www.lslog.com/plotting-a-global-path-to-blockbuster-sales-gsk-grabs-shingrix-nods-in-europe-japan/Plotting a global path to blockbuster sales, GSK grabs Shingrix nods in Europe, Japan

Plotting a global path to blockbuster sales, GSK grabs Shingrix nods in Europe, Japan

Plotting a global path to blockbuster sales, GSK grabs Shingrix nods in Europe, Japan As GlaxoSmithKline presses ahead with its Shingrix launch, the company picked up two important nods on Friday from […]

http://www.lslog.com/roches-hemlibra-gileads-biktarvy-top-pharmas-blockbuster-2018-launches-report/Roche's Hemlibra, Gilead's Biktarvy top pharma's blockbuster 2018 launches: report

Roche's Hemlibra, Gilead's Biktarvy top pharma's blockbuster 2018 launches: report

Roche’s Hemlibra, Gilead’s Biktarvy top pharma’s blockbuster 2018 launches: report A new report outlines 12 drugs launching this year that analysts expect will reel in big sales, with top drugmakers […]

http://www.lslog.com/should-p-value-thresholds-be-cut-to-raise-data-standards/Should p-value thresholds be cut to raise data standards?

Should p-value thresholds be cut to raise data standards?

Should p-value thresholds be cut to raise data standards? For decades, scientific studies have hinged on showing a p-value of less than 0.05 as evidence that a study readout is […]